Berl T, Cadnapaphornchai P, Harbottle J A, Schrier R W
J Clin Invest. 1974 Jan;53(1):219-27. doi: 10.1172/JCI107541.
Recent studies have demonstrated that the water diuresis associated with intravenous infusion of norepinephrine is mediated primarly by suppression of antidiuretic hormone (ADH) release. To investigate whether the increase in cerebral perfusion pressure with intravenous norepinephrine (0.5 mug/kg/min) is directly responsible for suppression of ADH release, the carotid circulation of dogs was pump-perfused bilaterally to selectively increase cerebral perfusion pressure. In six experiments cerebral perfusion pressure was increased from a mean of 125 to 151 mm Hg and then returned to 120 mm Hg. This maneuver was not associated with a reversible increase in renal water excretion. The possibility was also examined that norepinephrine exerts a direct central effect to suppress ADH release. In 12 experiments norepinephrine was infused into the carotid artery in a subpressor dose (0.12 mug/kg/min) estimated to equal the amount of the catecholamine reaching the cerebral circulation with intravenous norepinephrine. The urinary osmolality (Uosm) was not significantly altered with intracarotid norepinephrine (932 to 959 mosmol/kg H(2)O. The possibility was also examined that changes in autonomic neural tone from arterial baroreceptors is responsible for suppression of ADH release with intravenous norepinephrine. In sham-operated animals intravenous norepinephrine diminished Uosm from 1,034 to 205 mosmol/kg H(2)O (P<0.001) whereas in animals with denervated arterial baroreceptors intravenous norepinephrine was not associated with a significant alteration in Uosm (1,233 to 1,232 mosmol/kg) H(2)O. These different effects on urinary osmolality occurred in the absence of differences in plasma osmolality and volume status. The results therefore indicate that norepinephrine primarily suppresses ADH release by altering autonomic baroreceptor tone rather than by a direct central or pressor effect of the catecholamine. This same mechanism may be the primary pathway for other nonosmotic influences on ADH release.
近期研究表明,静脉输注去甲肾上腺素所引起的水利尿主要是通过抑制抗利尿激素(ADH)释放来介导的。为了研究静脉注射去甲肾上腺素(0.5微克/千克/分钟)导致的脑灌注压升高是否直接导致ADH释放受到抑制,对犬的双侧颈动脉循环进行泵灌注以选择性地升高脑灌注压。在6个实验中,脑灌注压从平均125毫米汞柱升高至151毫米汞柱,然后又回到120毫米汞柱。此操作并未伴随着肾水排泄的可逆性增加。还研究了去甲肾上腺素是否通过直接的中枢效应来抑制ADH释放。在12个实验中,以低于升压剂量(0.12微克/千克/分钟)的去甲肾上腺素注入颈动脉,该剂量估计等同于静脉注射去甲肾上腺素时到达脑循环的儿茶酚胺量。颈动脉内注射去甲肾上腺素后尿渗透压(Uosm)无显著改变(932至959毫摩尔/千克H₂O)。还研究了动脉压力感受器引起的自主神经张力变化是否是静脉注射去甲肾上腺素抑制ADH释放的原因。在假手术动物中,静脉注射去甲肾上腺素使Uosm从1034降至205毫摩尔/千克H₂O(P<0.001),而在动脉压力感受器去神经支配的动物中,静脉注射去甲肾上腺素与Uosm的显著改变无关(1233至1232毫摩尔/千克H₂O)。这些对尿渗透压的不同影响发生在血浆渗透压和容量状态无差异的情况下。因此,结果表明,去甲肾上腺素主要通过改变自主压力感受器张力来抑制ADH释放,而不是通过儿茶酚胺的直接中枢效应或升压效应。同样的机制可能是其他非渗透性影响ADH释放的主要途径。